- Price is above the Trend Line, keeping the weekly tape constructive.
- Activity pressure is positive on the latest completed week.
DAP
GER
Week ended 07 Aug 2026
Weekly Investor Report
Danaher Corporation · Healthcare · Diagnostics & Research
Latest close
174.9 EUR
3.8%
latest week
Weekly setup
Mixed setup
The weekly trend is not active. Price is 4.4% above the Trend Line and sits at 53.0% of its 52-week range. The latest completed week returned 3.8%, after a 0.6% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is expensive relative to peers. The latest news-sentiment score is 51/100. Near-term considerations: volume confirmation is below normal.
Setup score
43
out of 100
Latest Close
174.9 EUR
7 Aug 2026
1W Return
3.8%
latest completed week
4W Return
0.6%
short-term follow-through
12W Return
25.2%
quarterly tape
Trend Breadth
34.6%
18 of 52 weeks active
Volume Ratio
0.7x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Activity pressure is weak, so confirmation is not yet broad enough.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
3.8%
Latest completed week; four-week move 0.6%.
Indicator stack
19/77
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Recent
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
51/100
21 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is 4.4% above the Trend Line and sits at 53.0% of its 52-week range. The latest completed week returned 3.8%, after a 0.6% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.7x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.2812-week average 0.10
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure7/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.28Current proprietary activity-pressure read.
Buy signals1Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 0.6% over four weeks, 25.2% over 12 weeks, and 3.7% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year18
Trend breadth34.6%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure1.06Latest activity-pressure read.
Pressure change104.0%Four-week change in activity pressure.
Leadership-7.23Latest relative-leadership reading.
RS change-110.0%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is expensive relative to peers.
Factor week 09 Aug 2026
Financial statements through 31 Mar 2026
Field coverage 91%
Model confidence 85%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength16/100Blend of value, momentum, and quality. Underlying universe rank 85; rank 1 is best.
Value16/100Relative valuation strength. Underlying universe rank 85; rank 1 is best.
Quality65/100Profitability and accounting quality. Underlying universe rank 36; rank 1 is best.
Momentum41/100Medium-term price momentum. Underlying universe rank 60; rank 1 is best.
Growth31/100Revenue and earnings growth. Underlying universe rank 70; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Value-quality framework32/100Value and quality alignment from the Sharemaestro SVQF framework.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- 33.3x Price divided by trailing earnings.
- Price / sales
- 5.0x Market value relative to trailing revenue.
- EV / EBITDA
- 19.2x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- 3.9% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 58.9% Gross profit retained from each unit of revenue.
- Operating margin
- 19.2% Operating profit retained from revenue.
- Free-cash-flow margin
- 21.4% Free cash flow generated from revenue.
- Return on invested capital
- 5.4% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 2.9% Latest one-year revenue growth.
- EPS growth
- -5.7% Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- -0.7% Latest one-year free-cash-flow growth.
- Piotroski F-score
- 5/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- 0.7% Cash dividends relative to market value.
- Buyback yield
- 1.6% Net share repurchases relative to market value.
- Shareholder yield
- 2.3% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 1.8x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment51/100
Weighted news tone is neutral across 21 relevant articles.
3 positive · 16 neutral · 2 negativePatient CapitalRecent
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
Recent buy signal in the last 8 weeks
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-15.8%Distance below the 52-week high.
13-week volatility4.0%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher13 of 2613 weeks finished lower.
Best week+9.4%Week of 26 Jun.
Worst week-9.2%Week of 24 Apr.
Latest week+3.8%Week of 7 Aug.
Shape of recent returns
Strong gains4
Modest gains9
Flat weeks0
Modest losses8
Sharp losses5
Recent vol4.0%13-week weekly-return volatility.
Base vol4.5%52-week weekly-return volatility.
Up/down split26/26Count of positive and negative weeks in the 52-week window.
Average skew3.5% / -3.2%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorDE Healthcare
4-week rank36 / 78
Group average1.4%
Trend breadth39.7%
Trend39.7%active weekly trend signals
MD69.2%positive activity pressure
RS34.6%positive relative leadership
Four-week leaders
IndustryDE Diagnostics & Research
4-week rank4 / 6
Group average1.9%
Trend breadth33.3%
Trend33.3%active weekly trend signals
MD100.0%positive activity pressure
RS50.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape38/100
Trend, activity pressure, participation, and risk combine to a 38/100 tape read.
Indicator analysis26/100Latest 12-week confirmation: trend 0/12, activity pressure 7/12, relative leadership 0/12.
Activity pressure 0.28; No reversal markers Factors33/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 24 SVQF32/100Value and quality alignment from the Sharemaestro SVQF framework.
Composite rank 253.5 of 375 Patient CapitalRecentActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
Recent buy signal in the last 8 weeks Sentiment51/100Weighted news tone is neutral across 21 relevant articles.
Danaher Corp (NYSE: DHR) awards 15,402 RSUs to EVP Gregory Milosevich Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 174.9 EUR | 3.8% | 167.6 EUR | 198.0 EUR | 1.06 | -7.23 | 2.1K | Off |
| 31 Jul 2026 | 168.6 EUR | 0.1% | 168.5 EUR | 198.2 EUR | 1.05 | -8.30 | 4.7K | Off |
| 24 Jul 2026 | 168.4 EUR | -5.3% | 169.4 EUR | 198.4 EUR | 0.97 | -6.61 | 11.8K | Off |
| 17 Jul 2026 | 177.8 EUR | 2.2% | 170.3 EUR | 198.6 EUR | 0.84 | -0.46 | 4.2K | Off |
| 10 Jul 2026 | 173.9 EUR | 0.8% | 170.7 EUR | 198.8 EUR | 0.52 | -3.44 | 2.5K | Off |
| 3 Jul 2026 | 172.6 EUR | 1.5% | 171.4 EUR | 198.9 EUR | 0.25 | -6.88 | 121 | Off |
| 26 Jun 2026 | 170.1 EUR | 9.4% | 172.2 EUR | 198.9 EUR | 0.02 | -4.22 | 517 | Off |
| 19 Jun 2026 | 155.4 EUR | -0.7% | 173.1 EUR | 199.1 EUR | -0.30 | -13.60 | 315 | Off |
| 12 Jun 2026 | 156.5 EUR | -2.2% | 174.4 EUR | 199.3 EUR | -0.57 | -11.98 | 542 | Off |
| 5 Jun 2026 | 160.1 EUR | 2.0% | 175.5 EUR | 199.5 EUR | -0.85 | -10.70 | 1.8K | Off |
| 29 May 2026 | 157.0 EUR | 5.9% | 176.1 EUR | 199.7 EUR | -1.15 | -13.76 | 2.6K | Off |
| 22 May 2026 | 148.3 EUR | 6.1% | 177.1 EUR | 199.9 EUR | -1.30 | -17.99 | 4.0K | Off |
| 15 May 2026 | 139.8 EUR | -4.2% | 178.6 EUR | 200.2 EUR | -1.29 | -19.84 | 5.2K | Off |
| 8 May 2026 | 145.9 EUR | -4.5% | 179.9 EUR | 200.5 EUR | -1.24 | -17.96 | 3.5K | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.